Search research articles
Contact Us
Filters
Showing results (601-610 of 674) with videos related to
Page
of 68
Sort By:
Nature Communications
|
July 16, 2024
Metabolic imaging across scales reveals distinct prostate cancer phenotypes
Nikita Sushentsev, Gregory Hamm, Lucy Flint, et al.
The Journal of Pathology
|
July 2, 2019
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
Claire S Reader, Sabari Vallath, Colin W Steele, et al.
NPJ Breast Cancer
|
September 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Molecular Cancer Therapeutics
|
November 16, 2014
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel
Urs Hancox, Sabina Cosulich, Lyndsey Hanson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)
Nancy U Lin, Hao Guo, Jeffrey T Yap, et al.
The New England Journal of Medicine
|
January 8, 2015
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
Sara M Tolaney, William T Barry, Chau T Dang, et al.
The Prostate
|
December 1, 2016
Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model
Elizabeth M Masko, Mahmoud A Alfaqih, Keith R Solomon, et al.
Breast Cancer Research and Treatment
|
April 21, 2019
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
Jennifer R Bellon, Hao Guo, William T Barry, et al.
NPJ Breast Cancer
|
August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Page
of 68
Search research articles
Search
Showing results (601-610 of 674) with videos related to
Sort By:
Page
of 68
Nature Communications
|
July 16, 2024
Metabolic imaging across scales reveals distinct prostate cancer phenotypes
Nikita Sushentsev, Gregory Hamm, Lucy Flint, et al.
The Journal of Pathology
|
July 2, 2019
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
Claire S Reader, Sabari Vallath, Colin W Steele, et al.
NPJ Breast Cancer
|
September 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Molecular Cancer Therapeutics
|
November 16, 2014
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel
Urs Hancox, Sabina Cosulich, Lyndsey Hanson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)
Nancy U Lin, Hao Guo, Jeffrey T Yap, et al.
The New England Journal of Medicine
|
January 8, 2015
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
Sara M Tolaney, William T Barry, Chau T Dang, et al.
The Prostate
|
December 1, 2016
Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model
Elizabeth M Masko, Mahmoud A Alfaqih, Keith R Solomon, et al.
Breast Cancer Research and Treatment
|
April 21, 2019
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
Jennifer R Bellon, Hao Guo, William T Barry, et al.
NPJ Breast Cancer
|
August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Page
of 68